Cancer Medicine · global
Before Recurrence Appears on Imaging: University of Washington Recruits Patients for Phase II Ovarian Cancer Vaccine Trial
The IGFBP-2 vaccine trial targets patients with elevated CA-125 levels but no lesions visible on imaging, seeking to turn an early warning of recurrence into an opportunity for immune intervention. Whether it can delay disease progression remains to be clinically validated.
For patients who have completed ovarian cancer treatment, follow-up testing can sometimes bring unsettling uncertainty: tumor marker levels in the blood begin to rise, yet scans still show no lesions. The University of Washington’s Cancer Vaccine Institute in the United States is recruiting for a phase II clinical trial that aims to activate an immune response during this interval and test whether it can delay cancer progression.
The study, led by John Ben Liao and registered as NCT07495124, is funded by the Kuni Foundation. The institute’s recruitment page states that eligible patients include those with ovarian, fallopian tube, or primary peritoneal cancer who previously received platinum-containing chemotherapy and responded to initial treatment. Their shared characteristic is persistently rising CA-125 levels with no disease visible on imaging. Enrollment remains subject to the marker thresholds, physical condition requirements, and other criteria listed in the registry.
The vaccine targets insulin-like growth factor-binding protein 2 (IGFBP-2). The institute notes that this protein can be highly expressed in ovarian cancer cells. The concept behind this DNA vaccine is to teach the immune system to recognize the relevant antigens and then attack tumor cells bearing those features. Its purpose is to study disease control after treatment; it is not intended for vaccination of generally healthy people to prevent a first occurrence of cancer.
The regimen involves more than the vaccine alone. According to the design published by the U.S. National Cancer Institute, patients will first receive a single intravenous dose of carboplatin, followed two to three days later by the start of intradermal IGFBP-2 vaccinations, given every four weeks for up to three doses in the initial series. Fred Hutch Cancer Center explains that one reason for administering carboplatin first is that it may activate certain antitumor immune functions. Whether this sequence can enhance the subsequent vaccine’s effects is a hypothesis the study aims to test.
The trial’s central question is whether this regimen can improve recurrence-free survival rates and prolong progression-free survival. The study will also track overall survival and immune changes, including T-cell activation and exhaustion, to explore the relationship between immune responses and disease control. These measurements matter: even if the vaccine elicits a detectable immune response, that does not directly equate to a longer period of disease control for patients.
Another key consideration when interpreting future results is the method of comparison. The primary efficacy objective listed in the registry involves comparison with historical control data, rather than a concurrently randomized control group. Differences in patients’ preexisting disease status, prior treatments, and follow-up methods could therefore affect the comparison. Even if positive signals emerge, careful assessment will still be needed to determine how much can be attributed to the trial regimen.
What can currently be confirmed is that this phase II study is recruiting; this does not yet support a claim that the vaccine can prevent ovarian cancer recurrence. The study focuses on the stage when blood tests already show warning signs but imaging reveals no obvious lesions. If effective immune defenses can be established at this point, there may be an opportunity to delay disease progression. Whether that opportunity translates into an actual benefit for patients, however, remains to be answered through subsequent follow-up.